VDR Gene Polymorphisms and Weight Loss in Non-diabetic Overweight and Obese Subjects
Primary Purpose
Overweight, Obesity
Status
Completed
Phase
Not Applicable
Locations
India
Study Type
Interventional
Intervention
diet and exercise
Sponsored by

About this trial
This is an interventional basic science trial for Overweight
Eligibility Criteria
Inclusion Criteria:
- 20-60 yrs
- BMI ≥ 23 kg/m2
Exclusion Criteria:
- Type 1 or Type 2 Diabetes.
- On drugs or meal supplements for weight loss.
- On calcium and or vitamin D supplement currently or in the previous six months.
- Have past or current history or family history of renal stones.
- Have participated in any other investigational drug study in the previous three months.
- Have any systemic diseases (cardiac, hepatic, endocrine or renal) or taking any kind of treatment more than one month in the last six months.
- Diagnosed malabsorption (celiac disease, Cohn's, ulcerative colitis) or history suggestive of malabsorption.
- Have past history of bariatric surgery
Sites / Locations
- Anoop misra
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Diet and Exercise
Arm Description
Outcomes
Primary Outcome Measures
Body weight (Kg)
weight loss
Secondary Outcome Measures
Genetic polymorphism
BsmI, TaqI, ApaI, FokI
Full Information
NCT ID
NCT03386331
First Posted
July 26, 2017
Last Updated
February 3, 2021
Sponsor
Diabetes Foundation, India
Collaborators
Indian Council of Medical Research
1. Study Identification
Unique Protocol Identification Number
NCT03386331
Brief Title
VDR Gene Polymorphisms and Weight Loss in Non-diabetic Overweight and Obese Subjects
Official Title
The Influence of Vitamin D Receptor (VDR) Gene Polymorphisms (BsmI, TaqI, ApaI, FokI) on Weight Loss by Diet and Exercise Interventions in Non-diabetic Overweight and Obese Subjects
Study Type
Interventional
2. Study Status
Record Verification Date
February 2019
Overall Recruitment Status
Completed
Study Start Date
March 16, 2016 (Actual)
Primary Completion Date
March 30, 2019 (Actual)
Study Completion Date
March 30, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Diabetes Foundation, India
Collaborators
Indian Council of Medical Research
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a six months intervention study in non-diabetic overweight and obese subjects. Subjects will be counseled for weight loss through diet and exercise. Diet and exercise will be recommended as per the regular norms for weight loss (weight loss ≥10% from baseline weight will be considered as a significant loss of weight) for overweight and obese subjects. A sample size of 90 subjects was calculated but assuming a drop out rate of 20%, 110 subjects will be enrolled. Enrolled subjects will be measured at every visit (monthly) for weight, body composition measures of abdominal obesity and skin folds. They would be assessed for compliance with diet and exercise. Detailed analysis of body composition including DXA, biochemical analysis will be performed at enrollment and after six months intervention. Statistical analysis will be performed to find association between measures of body composition for weight loss and genotypes of the VDR polymorphisms.
Detailed Description
This is a six months intervention study in non-diabetic overweight and obese subjects. Subjects will be counseled for weight loss through diet and exercise. Diet and exercise will be recommended as per the regular norms for weight loss (weight loss ≥10% from baseline weight will be considered as a significant loss of weight) for overweight and obese subjects. A sample size of 90 subjects was calculated but assuming a drop out rate of 20%, 110 subjects will be enrolled. Enrolled subjects will be measured at every visit (monthly) for weight, body composition measures of abdominal obesity and skin folds. They would be assessed for compliance with diet and exercise. Detailed analysis of body composition including DXA, biochemical analysis will be performed at enrollment and after six months intervention. Statistical analysis will be performed to find association between measures of body composition for weight loss and genotypes of the VDR polymorphisms.
VDR Polymorphisms
Polymorphisms in the VDR gene have been identified through out the complete VDR gene region and associated with cancer and autoimmune diseases. The FokI polymorphism is present in the translation site and results in the VDR protein being shortened by three amino acids and is not linked with any other VDR polymorphisms. This polymorphism predisposes to bone-disease, risk of cancer, immune mediated diseases 147-149,150, 151.
The common VDR gene polymorphisms are BsmI, TaqI, ApaI and FokI. These polymorphisms have shown varying results with insulin sensitivity and secretion.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Overweight, Obesity
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
110 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Diet and Exercise
Arm Type
Other
Intervention Type
Behavioral
Intervention Name(s)
diet and exercise
Intervention Description
Diet and lifestyle intervention
Primary Outcome Measure Information:
Title
Body weight (Kg)
Description
weight loss
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Genetic polymorphism
Description
BsmI, TaqI, ApaI, FokI
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
20-60 yrs
BMI ≥ 23 kg/m2
Exclusion Criteria:
Type 1 or Type 2 Diabetes.
On drugs or meal supplements for weight loss.
On calcium and or vitamin D supplement currently or in the previous six months.
Have past or current history or family history of renal stones.
Have participated in any other investigational drug study in the previous three months.
Have any systemic diseases (cardiac, hepatic, endocrine or renal) or taking any kind of treatment more than one month in the last six months.
Diagnosed malabsorption (celiac disease, Cohn's, ulcerative colitis) or history suggestive of malabsorption.
Have past history of bariatric surgery
Facility Information:
Facility Name
Anoop misra
City
New Delhi
Country
India
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
VDR Gene Polymorphisms and Weight Loss in Non-diabetic Overweight and Obese Subjects
We'll reach out to this number within 24 hrs